Safety and Tolerability of Wharton's Jelly-Derived Mesenchymal Stem Cells for Patients With Duchenne Muscular Dystrophy: A Phase 1 Clinical Study.

导出 OA

翻译打印收藏纠错

作者： Jiwon,Lee ^[1] ; Sang Eon,Park ^[2] ; Mira,Kim ^[3] ; Hyeongseop,Kim ^[2] ; Jeong-Yi,Kwon ^[4] ; Hong Bae,Jeon ^[5] ; Jong Wook,Chang ^[6] ; Jeehun,Lee ^[7]

作者单位： Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ^[1] Cell and Gene Therapy Research Institute, ENCell Co. Ltd., Seoul, Korea.;Cell & Gene Therapy Institute, Samsung Medical Center, Seoul, Korea. ^[2] Clinical Development Department, ENCell Co. Ltd., Seoul, Korea. ^[3] Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ^[4] Cell and Gene Therapy Research Institute, ENCell Co. Ltd., Seoul, Korea. ^[5] Cell and Gene Therapy Research Institute, ENCell Co. Ltd., Seoul, Korea.;Cell & Gene Therapy Institute, Samsung Medical Center, Seoul, Korea.;Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea. ^[6] Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.;Cell & Gene Therapy Institute, Samsung Medical Center, Seoul, Korea. jhlee0101@skku.edu. ^[7]

关键词 Duchenne muscular dystrophy cell therapy mesenchymal stem cells phase 1 clinical trial

DOI 10.3988/jcn.2024.0299

PMID 39778566

发布时间 2025-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交